Consequences of Undiagnosed and Untreated Pain

Published Online: Thursday, October 20, 2011
Follow Pharmacy_Times:
Watch as Michael R. Clark, MD, MPH, MBA, associate professor and director of the Chronic Pain Treatment Programs and department of Psychiatry and Behavioral Sciences at Johns Hopkins Medical Institutions, talks about the consequences of pain going undiagnosed or untreated—particularly in terms of the impact on quality of life, and the importance of engaging patients early.

Related Articles
In response to a recent resurgence in fentanyl abuse, the DEA today issued a nationwide alert about the dangers of the drug, describing it as a threat to health and public safety.
From optimizing inhaler technique in patients with chronic obstructive pulmonary disease, to catching red flags when dispensing controlled substances to patients with chronic pain, pharmacists can improve patient outcomes in an evolving treatment landscape.
Mylan Inc. has introduced 3 generic versions of existing drugs to the US market, including the first and only available intermediate dosages of transdermal fentanyl.
More than 300 pharmacy students, technicians, and pharmacists helped raise nearly $6500 at the 2015 Mid-Year Conference of the Pennsylvania Pharmacists Association.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$